Endometrial cancer
References
Key articles
McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):16-22. Abstract
Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. Abstract
Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. Abstract
Obermair A, Janda M, Baker J, et al. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer. 2012 May;48(8):1147-53. Abstract
Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012 Jul;48(11):1638-48. Abstract
de Boer SM, Powell ME, Mileshkin L, et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb 12;19(3):295-309.Full text Abstract
Reference articles
1. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon, France: IARC Press; 2014.
2. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004 May;11(3):117-42. Abstract
3. Fadare O, Liang SX, Ulukus EC, et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol. 2006 Dec;30(12):1519-30. Abstract
4. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005 Sep 15;11(18):6422-30.Full text Abstract
5. Hoffman K, Nekhlyudov L, Deligdisch L. Endometrial carcinoma in elderly women. Gynecol Oncol. 1995 Aug;58(2):198-201. Abstract
6. Bhatla N, Denny L. FIGO Cancer Report 2018. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:2-3.Full text Abstract
7. Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50.Full text Abstract
8. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10-7. Abstract
9. Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tissue Res. 2005 Oct;322(1):53-61. Abstract
10. Santin AD. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol Oncol. 2003 Mar;88(3):263-5. Abstract
11. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997 Oct;17(2):143-4. Abstract
12. Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res. 1997 Nov 1;57(21):4736-8.Full text Abstract
13. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000 Feb 15;88(4):814-24. Abstract
14. Reinartz JJ, George E, Lindgren BR, et al. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol. 1994 Oct;25(10):1075-83. Abstract
15. Rolitsky CD, Theil KS, McGaughy VR, et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol. 1999 Apr;18(2):138-43. Abstract
16. Santin AD, Bellone S, Van Stedum S, et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005 Jul;98(1):24-30. Abstract
17. Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004 Aug 1;22(15):3126-32.Full text Abstract
18. Hetzel DJ, Wilson TO, Keeney GL, et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol. 1992 Nov;47(2):179-85. Abstract
19. Kandoth C, Schultz N, et al; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 2;497(7447):67-73. [Erratum in: Nature. 2013 Aug 8;500(7461):242.]Full text Abstract
20. Clarke MA, Long BJ, Del Mar Morillo A, et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA Intern Med. 2018 Sep 1;178(9):1210-22. Abstract
21. Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006 Jun;101(3):470-5. Abstract
22. Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005 Mar;105(3):575-80. Abstract
23. Gu M, Shi W, Barakat RR, et al. Pap smears in women with endometrial carcinoma. Acta Cytol. 2001 Jul-Aug;45(4):555-60. Abstract
24. Eddy GL, Wojtowycz MA, Piraino PS, et al. Papanicolaou smears by the Bethesda system in endometrial malignancy: utility and prognostic importance. Obstet Gynecol. 1997 Dec;90(6):999-1003. Abstract
25. de Haydu C, Black JD, Schwab CL, et al. An update on the current pharmacotherapy for endometrial cancer. Expert Opin Pharmacother. 2015 Dec 23;17(4):489-99. Abstract
26. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Sep 12;68(6):394-424.Full text Abstract
27. Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016 Nov 7;34(35):4225-30.Full text Abstract
28. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30.Full text Abstract
29. National Cancer Institute. Surveillance epidemiology and end results (SEER). Cancer stat facts: uterine cancer. 2019 [internet publication].Full text
30. Horn LC, Meinel A, Handzel R, et al. Histopathology of endometrial hyperplasia and endometrial carcinoma: an update. Ann Diagn Pathol. 2007 Aug;11(4):297-311. Abstract
31. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985 Jul 15;56(2):403-12. Abstract
32. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008 May;21(5):591-8.Full text Abstract
33. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995 Feb;85(2):304-13. Abstract
34. Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017 Jan 17;(1):CD004143.Full text Abstract
35. Hemminki K, Granstrom C. Familial clustering of ovarian and endometrial cancers. Eur J Cancer. 2004 Jan;40(1):90-5. Abstract
36. Lu KH, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch II syndrome in young women with endometrial cancer. J Clin Oncol. 2007 Nov 20;25(33):5158-64. Abstract
37. Thompson D, Easton DF; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65.Full text Abstract
38. Chubak J, Tworoger SS, Yasui Y, et al. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1296-301. Abstract
39. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000 Jun 7;92(11):924-30.Full text Abstract
40. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and PTEN in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005 Jan;11(1):63-70. Abstract
41. Ambros RA, Sherman ME, Zahn CM, et al. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol. 1995 Nov;26(11):1260-7. Abstract
42. Peiró G, Mayr D, Hillemanns P, et al. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol. 2004 Mar;17(3):277-87.Full text Abstract
43. del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012 Dec;127(3):651-61. Abstract
44. O'Mara TA, Glubb DM, Amant F, et al. Identification of nine new susceptibility loci for endometrial cancer. Nat Commun. 2018 Aug 9;9(1):3166.Full text Abstract
45. Crosbie EJ, Roberts C, Qian W, et al. Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer. 2011 Nov 17;48(6):853-64.Full text Abstract
46. Modesitt SC, Tian C, Kryscio R, et al. Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Apr;105(1):59-65. Abstract
47. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007 Dec 1;335(7630):1134.Full text Abstract
48. Jenabi E, Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis. Public Health. 2015 Jul;129(7):872-80.Full text Abstract
49. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996 Aug 21;88(16):1127-35.Full text Abstract
50. Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. Compr Physiol. 2012 Apr;2(2):1143-211.Full text Abstract
51. Viswanathan AN, Feskanich D, De Vivo I, et al. Smoking and the risk of endometrial cancer: results from the Nurses' Health Study. Int J Cancer. 2005 May 10;114(6):996-1001.Full text Abstract
52. Duska L, Shahrokni A, Powell M. Treatment of older women with endometrial cancer: improving outcomes with personalized care. Am Soc Clin Oncol Educ Book. 2016;35:164-74.Full text Abstract
53. Royal College of Obstetricians and Gynaecologists. Management of endometrial hyperplasia. Feb 2016 [internet publication].Full text
54. Travaglino A, Raffone A, Saccone G, et al. Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: A specific marker of precancer and novel indication for treatment: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018 Dec;97(12):1415-1426.Full text Abstract
55. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006 Feb 15;106(4):812-9.Full text Abstract
56. Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 2019 Oct 1;145(7):1719-1730.Full text Abstract
57. Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncol. 2018 Apr 1;4(4):516-521.Full text Abstract
58. Neven P, De Muylder X, Van Belle Y, et al. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet. 1998 Jan 3;351(9095):36. Abstract
59. Magriples U, Naftolin F, Schwartz PE, et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993 Mar;11(3):485-90. Abstract
60. Ferguson SE, Soslow RA, Amsterdam A, et al. Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol. 2006 May;101(2):322-6. Abstract
61. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol. 2006 Jun;107(6):1475-8. Abstract
62. Zhang ZH, Su PY, Hao JH, et al. The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies. Int J Gynecol Cancer. 2013 Feb;23(2):294-303. Abstract
63. Luo J, Beresford S, Chen C, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014 Jul 22;111(7):1432-9.Full text Abstract
64. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol. 2015 Jan;125(1):89-98.Full text Abstract
65. Johnatty SE, Tan YY, Buchanan DD, et al. Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecol Oncol. 2017 Nov;147(2):381-387.Full text Abstract
66. Lynch HT, Krush AJ, Lemon HM, et al. Tumor variation in families with breast cancer. JAMA. 1972 Dec 25;222(13):1631-5. Abstract
67. Koornstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol. 2009 Apr;10(4):400-8. Abstract
68. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009 Feb;75(2):141-9. Abstract
69. Bubien V, Bonnet F, Brouste V, et al; French Cowden Disease Network. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013 Jan 18;50(4):255-63. Abstract
70. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012 May;27(5):1327-31.Full text Abstract
71. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014 Sep-Oct;20(5):748-58.Full text Abstract
72. Pothuri B, Ramondetta L, Eifel P, et al. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol. 2006 Dec;103(3):948-51.Full text Abstract
73. Liu JR, Conaway M, Rodriguez GC, et al. Relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol. 1995 Oct;86(4 Pt 1):486-90. Abstract
74. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007 Nov;107(2):159-62. Abstract
75. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006 Jan 19;354(3):261-9.Full text Abstract
76. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Jan 2021 [internet publication].Full text
77. Saso S, Chatterjee J, Georgiou E, et al. Endometrial cancer. BMJ. 2011 Jul 6;343:d3954. Abstract
78. Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016 Mar 15;93(6):468-74.Full text Abstract
79. Pennant ME, Mehta R, Moody P, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017 Feb;124(3):404-411.Full text Abstract
80. Castellano T, Ding K, Moore KN, et al. Simple Hysterectomy for Cervical Cancer: Risk Factors for Failed Screening and Deviation From Screening Guidelines. J Low Genit Tract Dis. 2019 Apr;23(2):124-128.Full text Abstract
81. Gredmark T, Kvint S, Havel G, et al. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol. 1995 Feb;102(2):133-6. Abstract
82. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 734: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol. 2018 May;131(5):e124-9.Full text Abstract
83. American Institute of Ultrasound in Medicine, American College of Radiology., American College of Obstetricians and Gynecologists, Society of Radiologists in Ultrasound. AIUM practice guideline for the performance of sonohysterography. J Ultrasound Med. 2015 Aug;34(8):1-6.Full text Abstract
84. Larson DM, Johnson KK, Broste SK, et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol. 1995 Jul;86(1):38-42. Abstract
85. Huang GS, Gebb JS, Einstein, MH, et al. Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol. 2007 Mar;196(3):243.e1-5. Abstract
86. Schnatz PF, Guile M, O'Sullivan DM, et al. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol. 2006 Mar;107(3):701-8. Abstract
87. Chang MC, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis. Eur J Radiol. 2012 Nov;81(11):3511-7. Abstract
88. Kitajima K, Murakami K, Yamasaki E, et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Ann Nucl Med. 2008 Mar 3;22(2):103-9. Abstract
89. Sharma P, Kumar R, Singh H, et al. Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med. 2012 Jul;37(7):649-55. Abstract
90. Kadkhodayan S, Shahriari S, Treglia G, et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol. 2012 Oct 26;128(2):397-404. Abstract
91. Creasman WT, DeGeest K, DiSaia PJ, et al. Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1999 Jul;181(1):31-4. Abstract
92. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009 May;105(2):103-4. [Erratum in: Int J Gynaecol Obstet. 2010 Feb;108(2):176.] Abstract
93. McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 Jul;106(1):16-22. Abstract
94. Cho KR, Cooper K, Croce S, et al. International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S114-S122.Full text Abstract
95. Wang JZ, Xiong YJ, Man GCW, et al. Clinicopathological and prognostic significance of blood microvessel density in endometrial cancer: a meta-analysis and subgroup analysis. Arch Gynecol Obstet. 2018 Mar;297(3):731-740.Full text Abstract
96. Clark TJ, Barton PM, Coomarasamy A, et al. Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies. BJOG. 2006 May;113(5):502-10. Abstract
97. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998 Nov 4;280(17):1510-7. Abstract
98. American College of Radiology. ACR appropriateness criteria: abnormal vaginal bleeding. 2014 [internet publication].Full text
99. American College of Radiology. ACR appropriateness criteria: pretreatment evaluation and follow-up of endometrial cancer. 2020 [internet publication].Full text
100. Renaud MC, Le T, Bentley J, et al; SOGC-GOC-SCC Policy and Practice Guidelines Committee. Epidemiology and investigations for suspected endometrial cancer. J Obstet Gynaecol Can. 2013 Apr;35(4):380-1.Full text Abstract
101. Kinkel K, Kaji Y, Yu KK, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology. 1999 Sep;212(3):711-8. Abstract
102. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. Abstract
103. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Mar;92(3):744-51. Abstract
104. Creutzberg CL, van Putten WL, Koper PC, et al; PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000 Apr 22;355(9213):1404-11. Abstract
105. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2015 Dec 2;27(1):16-41.Full text Abstract
106. Lancaster JM, Powell CB, Chen LM, et al; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2014 Sep 17;136(1):3-7. [Erratum in: Gynecol Oncol. 2015 Sep;138(3):765.] Abstract
107. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta Obstet Gynecol Scand. 2011 May;90(5):437-44. Abstract
108. Committee on Practice Bulletins-Gynecology., Society of Gynecologic Oncology. ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol. 2014 Nov;124(5):1042-54. Abstract
109. Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol. 2003 Oct;91(1):154-9. Abstract
110. Love CD, Muir BB, Scrimgeour JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol. 1999 Jul;17(7):2050-4. Abstract
111. Demirkiran F, Arvas M, Erkun E, et al. The prognostic significance of cervico-vaginal cytology in endometrial cancer. Eur J Gynaecol Oncol. 1995;16(5):403-9. Abstract
112. Bristow RE, Purinton SC, Santillan A, et al. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol. 2006 Nov;103(2):709-13. Abstract
113. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: uterine neoplasms [internet publication].Full text
114. Wolfman W, Leyland N, Heywood M, et al. Asymptomatic endometrial thickening. J Obstet Gynaecol Can. 2010 Oct;32(10):990-9.Full text Abstract
115. Colombo N, Preti E, Landoni F, et al; ESMO Guidelines Working Group. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi33-8.Full text Abstract
116. Fiorelli JL, Herzog TJ, Wright JD. Current treatment strategies for endometrial cancer. Expert Rev Anticancer Ther. 2008 Jul;8(7):1149-57. Abstract
117. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005 Aug 6-12;366(9484):491-505. Abstract
118. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer. 1987 Oct 15;60(8 Suppl):2035-41. Abstract
119. Bodurtha Smith AJ, Fader AN, Tanner EJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016 Nov 18;216(5):459-76.e10.Full text Abstract
120. Soliman PT, Westin SN, Dioun S, et al. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 May 18;146(2):234-9.Full text Abstract
121. Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017 Feb 1;18(3):384-92. Abstract
122. Holloway RW, Abu-Rustum NR, Backes FJ, et al. Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol. 2017 May 28;146(2):405-15.Full text Abstract
123. Bogani G, Murgia F, Ditto A, et al. Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol. 2019 Jun;153(3):676-683.Full text Abstract
124. How JA, O'Farrell P, Amajoud Z, et al. Sentinel lymph node mapping in endometrial cancer: a systematic review and meta-analysis. Minerva Ginecol. 2018 Apr;70(2):194-214.Full text Abstract
125. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991 Jan;40(1):55-65. Abstract
126. Badger C, Preston N, Seers K, et al. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003141.Full text Abstract
127. Galaal K, Donkers H, Bryant A, et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev. 2018 Oct 31;(10):CD006655.Full text Abstract
128. Zhang H, Cui J, Jia L, et al. Comparison of laparoscopy and laparotomy for endometrial cancer. Int J Gynaecol Obstet. 2012 Mar;116(3):185-91. Abstract
129. Obermair A, Janda M, Baker J, et al. Improved surgical safety after laparoscopic compared to open surgery for apparent early stage endometrial cancer: results from a randomised controlled trial. Eur J Cancer. 2012 May;48(8):1147-53. Abstract
130. Lin F, Zhang QJ, Zheng FY, et al. Laparoscopically assisted versus open surgery for endometrial cancer - a meta-analysis of randomized controlled trials. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1315-25. Abstract
131. de la Orden SG, Reza MM, Blasco JA, et al. Laparoscopic hysterectomy in the treatment of endometrial cancer: a systematic review. J Minim Invasive Gynecol. 2008 Jul-Aug;15(4):395-401. Abstract
132. Ju W, Myung SK, Kim Y, et al. Comparison of laparoscopy and laparotomy for management of endometrial carcinoma: a meta-analysis. Int J Gynecol Cancer. 2009 Apr;19(3):400-6. Abstract
133. Jørgensen SL, Mogensen O, Wu C, et al. Nationwide introduction of minimally invasive robotic surgery for early-stage endometrial cancer and its association with severe complications. JAMA Surg. 2019 Feb 27 [Epub ahead of print]. Abstract
134. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar 1;30(7):695-700.Full text Abstract
135. Ind T, Laios A, Hacking M, et al. A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: A systematic review and meta-analysis. Int J Med Robot. 2017 Dec;13(4):.Full text Abstract
136. Gaia G, Holloway RW, Santoro L, et al. Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches: a systematic review. Obstet Gynecol. 2010 Dec;116(6):1422-31. Abstract
137. Orton J, Blake P. Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trial. Paper presented at: 2007 meeting of the American Society of Clinical Oncology (ASCO). J Clin Oncol. 2007 Jun 20;25(18_Suppl):5504.Full text
138. Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol. 2008 Apr;109(1):11-8. Abstract
139. Giede C, Le T, Power P, et al; SOGC-GOC-SCC Policy and Practice Guideline Committee. The role of surgery in endometrial cancer. J Obstet Gynaecol Can. 2013 Apr;35(4):370-1.Full text Abstract
140. Khoury-Collado F, Abu-Rustum NR. Lymphatic mapping in endometrial cancer: a literature review of current techniques and results. Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1163-8. Abstract
141. Frost JA, Webster KE, Bryant A, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2017 Oct 2;(10):CD007585.Full text Abstract
142. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009 Jan 10;373(9658):125-36.Full text Abstract
143. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16. Abstract
144. Bristow RE, Zahurak ML, Alexander CJ, et al. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer. 2003 Sep-Oct;13(5):664-72. Abstract
145. Chi DS, Welshinger M, Venkatraman ES, et al. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol. 1997 Oct;67(1):56-60. Abstract
146. Bristow RE, Zerbe MJ, Rosenshein NB, et al. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol. 2000 Aug;78(2):85-91. Abstract
147. DeLaney T, Penson R. Radiotherapy and post-surgical management of endometrial cancer. In: Berkowitz RS, ed. Endometrial cancer. Hamilton, Canada: BC Decker; 2004:106-26.
148. Nout RA, Smit VT, Putter H, et al; PORTEC Study Group. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010 Mar 6;375(9717):816-23. Abstract
149. Kupets R, Le T, Bentley J, et al; SOGC-GOC-SCC Policy and Practice Guidelines Committee. The role of adjuvant therapy in endometrial cancer. J Obstet Gynaecol Can. 2013 Apr;35(4):375-6.Full text Abstract
150. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006 Jan 1;24(1):36-44.Full text Abstract
151. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006 Aug 7;95(3):266-71.Full text Abstract
152. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008 Jan;108(1):226-33. Abstract
153. Mundt AJ, McBride R, Rotmensch J, et al. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1145-53. Abstract
154. Wortman BG, Creutzberg CL, Putter H, et al; PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018 Oct 25;119(9):1067-74.Full text Abstract
155. Creutzberg CL, Nout RA, Lybeert ML, et al; PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e631-8. Abstract
156. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012 Apr 18;(4):CD003916.Full text Abstract
157. Einhorn N, Trope C, Ridderheim M, et al. A systematic overview of radiation therapy effects in uterine cancer (corpus uteri). Acta Oncol. 2003;42(5-6):557-61. Abstract
158. Lanciano RM, Curran WJ, Jr., Greven KM, et al. Influence of grade, histologic subtype, and timing of radiotherapy on outcome among patients with stage II carcinoma of the endometrium. Gynecol Oncol. 1990 Dec;39(3):368-73. Abstract
159. Lawrie TA, Green JT, Beresford M, et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev. 2018 Jan 23;(1):CD012529.Full text Abstract
160. Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer. 2012 Jul;48(11):1638-48. Abstract
161. Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011 May 1;29(13):1692-700.Full text Abstract
162. Onsrud M, Cvancarova M, Hellebust TP, et al. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol. 2013 Nov 1;31(31):3951-6.Full text Abstract
163. Kwak YK, Lee SW, Kay CS, et al. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose. PLoS One. 2017 Aug 28;12(8):e0183339.Full text Abstract
164. Klopp AH, Yeung AR, Deshmukh S, et al. Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG Oncology-RTOG 1203. J Clin Oncol. 2018 Jul 10;36(24):2538-44.Full text Abstract
165. Mundt AJ, Murphy KT, Rotmensch J, et al. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001;50:1154-1160. Abstract
166. Vargo JA, Boisen MM, Comerci JT, et al. Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. Gynecol Oncol. 2014 Nov;135(2):190-5. Abstract
167. de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019 Sep;20(9):1273-1285.Full text Abstract
168. Yi L, Zhang H, Zou J, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis. Gynecol Oncol. 2018 Jun;149(3):612-619.Full text Abstract
169. de Boer SM, Powell ME, Mileshkin L, et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Feb 12;19(3):295-309.Full text Abstract
170. Randall ME, Filiaci V, McMeekin DS, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol. 2019 Apr 17 [Epub ahead of print]. Abstract
171. Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001 Jan 15;19(2):364-7. Abstract
172. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999 Jun;17(6):1736-44. Abstract
173. Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):10-4. Abstract
174. Skeel RT, Khleif S (eds). Handbook of cancer chemotherapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.
175. Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007 Sep-Oct;17(5):964-78. Abstract
176. Polyzos NP, Pavlidis N, Paraskevaidis E, et al. Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: an overview of survival data. Eur J Cancer. 2006 Feb;42(3):319-26. Abstract
177. Lentz SS. Endocrine therapy of endometrial cancer. Cancer Treat Res. 1998;94:89-106. Abstract
178. Martin-Hirsch PP, Bryant A, Keep SL, et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD001040.Full text Abstract
179. Sorbe B, Nordstrom B, Maenpaa J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009 Jul;19(5):873-8. Abstract
180. Klopp A, Smith BD, Alektiar K, et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014 May-Jun;4(3):137-44.Full text Abstract
181. Jones E, Beriwal S, Beyer D, et al. An analysis of appropriate delivery of postoperative radiation therapy for endometrial cancer using the RAND/UCLA Appropriateness Method: executive summary. Adv Radiat Oncol. 2015 Dec 17;1(1):26-34.Full text Abstract
182. Gunderson CC, Fader AN, Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012 May;125(2):477-82. Abstract
183. Baker JO. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012 Apr;125(1):263-70. Abstract
184. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2004 Jun 1;22(11):2159-66.Full text Abstract
185. Miller D, Filiaci V, Gelming G, et al. Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2012 Jun;125(3):771-3.Full text
186. Nomura H, Aoki D, Michimae H, et al. Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: a randomized clinical trial. JAMA Oncol. 2019 Mar 21 [Epub ahead of print]. Abstract
187. Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol. 2011 Apr;121(1):112-7.Full text Abstract
188. Lu SM, Chang-Halpenny C, Hwang-Graziano J. Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometroid adenocarcinoma. Gynecol Oncol. 2015 Apr;137(1):28-33. Abstract
189. Matei D, Filiaci V, Randall ME, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019 Jun 13;380(24):2317-2326.Full text Abstract
190. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S247-57. Abstract
191. Creutzberg CL, van Putten WL, Koper PC, et al; PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003 May;89(2):201-9. Abstract
192. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1366-72. Abstract
193. Ho JC, Allen PK, Jhingran A, et al. Management of nodal recurrences of endometrial cancer with IMRT. Gynecol Oncol. 2015 Oct;139(1):40-6. Abstract
194. Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004 Jan;92(1):4-9. Abstract
195. Sjoquist KM, Martyn J, Edmondson RJ, et al. The role of hormonal therapy in gynecological cancers - current status and future directions. Int J Gynecol Cancer. 2011 Oct;21(7):1328-33. Abstract
196. Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 Study. J Clin Oncol. 2017 May 10;35(22):2535-41.Full text Abstract
197. De Felice F, Marchetti C, Tombolini V, et al. Immune check-point in endometrial cancer. Int J Clin Oncol. 2019 Aug;24(8):910-916.Full text Abstract
198. Duska LR, Berkowitz R, Matulonis U, et al. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan;96(1):198-203. Abstract
199. Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Follow-up after primary therapy for endometrial cancer: a systematic review. Jan 2006 (endorsed Jun 2017) [internet publication].Full text
200. Naumann RW. The role of the phosphatidylinositol 3-kinase (PI3K) pathway in the development and treatment of uterine cancer. Gynecol Oncol. 2011 Nov;123(2):411-20. Abstract
201. Myers AP, Cantley LC. Targeting a common collaborator in cancer development. Sci Transl Med. 2010 Sep 8;2(48):48ps45. Abstract
202. Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 Mar 25;20(5):711-718. Abstract
203. Wahl AO, Gaffney DK, Jhingran A, et al. ACR appropriateness criteria® adjuvant management of early-stage endometrial cancer. Oncology (Williston Park). 2016 Sep 15;30(9):816-22.Full text Abstract
204. American College of Obstetricians and Gynecologists; Society of Gynecologic Oncology. Practice bulletin no. 149: endometrial cancer. Apr 2015 [internet publication].Full text
205. Burke WM, Orr J, Leitao M, et al; SGO Clinical Practice Endometrial Cancer Working Group, Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014 Aug;134(2):385-92.Full text Abstract
206. Burke WM, Orr J, Leitao M, et al; SGO Clinical Practice Endometrial Cancer Working Group, Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: a review and current management strategies: part II. Gynecol Oncol. 2014 Aug;134(2):393-402.Full text Abstract
207. National Cancer Institute. SEER. Cancer Stat Facts: Uterine Cancer. 2016 [internet publication].Full text
208. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018 May 15;5:CD008830.Full text Abstract
209. Cella D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol. 2010 Dec;119(3):538-42. Abstract
210. Vergote I, Kjorstad K, Abeler V, et al. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer. 1989 Sep 1;64(5):1011-6. Abstract
Use of this content is subject to our disclaimer